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Abstract
Quinine is a naturally occurring alkaloid found in the bark of the South American cinchona 
tree. It is used to treat malaria, to relieve nocturnal leg cramps and is used as an antipyretic. 
Anecdotal evidence, especially from community pharmacists, suggests widespread misuse of 
quinine sulphate. It has been taken for a range of non-indicated uses ranging from a single 
dose monthly contraceptive to a post coital “morning after” contraceptive.
A self-administered questionnaire, together with a confidentiality and anonymity declaration, 
was offered to all females requesting quinine sulphate at a pharmacy in Hillbrow, 
Johannesburg. After completing the questionnaire, the participants were counselled on the 
proper indications, as well as the consequences of misuse of quinine.
Biostatisticians at the Medical Research Council, Pretoria, statistically analyzed results of the 
questionnaire. The results showed that the majority of participants intended using quinine 
sulphate for contraceptive purposes. The dosages, quantity and the time of use in relation to 
the menstrual cycle varied considerably. Advice and counselling from pharmacists, in 
particular, has been lacking. A loophole in the scheduling status of quinine makes it easy to 
acquire quinine under the guise of using it to treat nocturnal leg cramps, whereas it is actually 
use for non-indicated purposes.
The misuse is largely limited to black South African women of different ethnic backgrounds. 
The results of the survey are discussed with reference to the statistical analysis and 
recommendations are made to limit the abuse of quinine sulphate.
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Chapter 1 Introduction
1.1 Background
For over 300 years, quinine was the drug of choice for the treatment and chemosuppression 
of malaria.1 By 1959, quinine as an antimalarial had been totally superceded by synthetic 
antimalarials. However, the appearance of chloroquine-resistant strains of Plasmodium 
falciparum (P. falciparum) has led to a resurgence in the use of quinine. Of the thirty-six 
alkaloids found in the bark of the South American cinchona tree {Cinchona succirubra), 
four stereoisomers: quinine; quinidine; cinchonine; and cinchonidine have significant 
antimalarial activity. Quinine is present in highest concentration, exceeding the other 
active antimalarial compounds by about ten-fold.1
Quinine has little effect on smooth muscle other than a slight oxytocic action on the gravid 
uterus, especially during the third trimester of pregnancy. Clinically, it has no effect on 
pregnancy until labour has started. Dangerously toxic amounts may cause abortion.1
Other uses of quinine include relief of leg cramps occurring during recumbence at night. In 
many parts of the world quinine is still used as an all-purpose antipyretic.1
Anecdotal reports from a number of pharmacists, from newly qualified to those in practice 
for many years, suggest that mainly black South Africans use quinine sulphate for 
contraception or termination of pregnancy (TOP). Quinine has a dual registration status in 
South Africa. It is schedule one for use as a muscle relaxant in nocturnal cramps, and 
schedule four when used to treat malaria caused by P.falciparum. A secondary registration 
is the use of quinine sulphate in the diagnosis of myasthenia gravis.2
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1.2 Aims
1.2.1 To assess the extent of non-indicated usage of quinine sulphate amongst different 
population groups, but especially amongst black females in the Hillbrow-Berea 
area.
1.2.2 To assess the contribution of the healthcare professional in propagating the misuse 
of quinine sulphate.
1.2.3 Knowledge of quinine use:
1.2.3.1 To quantify the demand for quinine sulphate for use as a contraceptive, in a 
Hillbrow pharmacy.
1.2.3.2 To identify the source of the respondent’s knowledge on the use of quinine for 
contraceptive purposes.
1.2.3.3 To identify any association between population group, income group, age group 
and use of quinine as a contraceptive.
The most important outcome measures will be:
a) Reason for quinine usage;
b) Duration of quinine use;
c) Dosages used;
d) Concurrent contraceptive use.
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Chapter 2 Overview of quinine
2.1 The use of quinine as an antimalarial in pregnancy
Currently the only recommended treatment for uncomplicated, multidrug-resistant 
P.falciparum infections in pregnant women is quinine (thirty milligrams per kilogram per 
day) for seven days, but adverse effects are common and compliance is poor. Among the 
adverse effects are cinchonism, which is characterized by tinnitus and dizziness. Amongst 
the outcomes of pregnant mothers treated with quinine, possible complications include 
abortion and congenital abnormalities.3 Quinine should not be withheld during pregnancy, 
despite its alleged abortifacient properties at high dosage, since it safeguards the life of the 
mother.4
2.2 The use of quinine as a contraceptive or abortifacient
Quinine is reported to have contraceptive properties. It was used in Britain before the 
advent of oral contraceptives.4 In the early part of the twentieth century, in addition to 
being used as an abortifacient, quinine was also used as an emmenagogue or menstrual 
regulator.5 A study conducted among school adolescents in Benin City, Nigeria showed 
that 4% of females between fourteen and twenty one years of age had reportedly used 
quinine as a contraceptive.6 Dannenberg, Dorfinan and Johnson (1983) completed an 
extensive review of the literature concerning the efficacy of quinine as an abortifacient. 
Their results were unclear because of a lack of controlled studies and the large number of 
unreported cases. Of the reported cases, the results were startling. In seventy cases in 
which quinine was used to attempt to abort a known or suspected pregnancy, at least 
eleven cases resulted in the death of the mother. Abortion was achieved without death of 
the mother in only three cases. At least fifty-one offspring had congenital anomalies for 
which quinine was the suspected etiologic agent.7
2.3 Mechanism of abortifacient action.
Quinine has a slightly oxytocic action on the gravid uterus. The pregnant uterus is 
stimulated to contract by quinine, but the drug is no longer used in obstetric practice. The
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exact mechanism of action of quinine on the uterine muscle is unclear. Among the laity,
2.4 Chemistry of quinine
Although quinine has been synthesised, the procedure is complex; quinine and the other 
alkaloids are, therefore, still obtained entirely from natural sources. Quinine contains a 
quinoline group attached through a secondary alcohol linkage to a quinuclidine ring. A
2.5 Commercial preparations of quinine
Quinine sulphate is commercially available as a scheduled medicinal product via 
pharmacies, hospitals, clinics and dispensing doctors. Quinine is available as quinine 
dihydrochloride injection containing three hundred milligrams per millilitre (schedule 
four). It is also found commercially as quinine hydrochloride, which is one of six active 
ingredients in Ilvico tablets, a cold and flu preparation (twenty milligrams per tablet). The 
inclusion of quinine is probably for it’s antipyretic activity, although the preparation also 
contains salicylamide, which is an antipyretic. Quinine sulphate is available in three 
hundred milligram strength tablets and is schedule one for the use as a muscle relaxant in 
nocturnal cramps, and schedule four when used to treat malaria caused by P.falciparum.10
• * 8quinine has a reputation as an abortifacient.
methoxy side chain is attached to the quinoline ring and a vinyl to the quinuclidine.9
Quinine
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Chapter 3 Methods
3.1 Setting
The survey was conducted in a pharmacy in Hillbrow, Johannesburg, Gauteng, South 
Africa. The pharmacy has a patronage of about between 300-350 people per day and serves 
consumers/patients in the greater Hillbrow and Berea areas of Johannesburg, and to a 
lesser degree, residents of Yeoville and Joubert Park.
3.2 Timing
The survey was conducted over a period of five months between August 2001 and 
December 2001 at Tower Pharmacy in Pretoria street, Hillbrow.
3.3 Study population
The study population is a working class middle- to low-income group in an urban setting. 
Families reside mostly in blocks of flats. The area includes Hillbrow, Berea and to a lesser 
degree, Joubert Park and Yeoville. Population groups present are mainly black of different 
ethnic South African backgrounds, as well as immigrant blacks from African countries, 
including Zimbabwe, Mozambique, Malawi, Democratic Republic of Congo, Nigeria, 
Angola, Mali and Ethiopia.
3.4 Study sample
The study sample was limited to any female requesting to purchase quinine at Tower 
Pharmacy in Hillbrow. A total of 100 females were surveyed.
3.5 Questionnaire
A confidential self-administered questionnaire (Appendix 1) was offered to the 
participants, together with a Confidentiality and Anonymity Assurance (Appendix 2). 
Patients were offered the opportunity to use an interpreter if they were unable to 
understand the questionnaire, which was in English. The questionnaire consisted of sixteen 
questions of a categorical nature.
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3.6 Ethical considerations
The research was conducted on a female population, the majority of them of childbearing 
age. Participants were given the Confidentiality and Anonymity Assurance form, which 
also included an information sheet. Verbal consent was obtained from the participants prior 
to them completing the questionnaire. Following the interview, the intended use of quinine 
was established. The participant was then counselled on the availability of free family 
planning services in the area, as well as the side effects of quinine in both long- and short­
term use, and of the registered indications of quinine. Any additional questions from them 
were answered. The protocol was submitted to the Committee for Research on Human 
Subjects in April 2001 and permission was granted to conduct this study. The clearance 
certificate number is MO 1-05-41 (Appendix 3).
14
Chapter 4 Results
4.1 Statistical analysis
All questionnaires were individually coded. A total of 100 questionnaires were completed. 
The response rate was 100%. The coded data was sent to the Medical Research Council in 
Pretoria for analysis.
4.2 Frequency tables
4.2.1 Why are you using quinine ?
Reason for quinine usage
Frequency Percent Valid
Percent
Cumulative
Percent
Valid:
> To treat/prevent malaria 10 10 10 10
> To treat/prevent nocturnal cramps 3 3 3 13
> To prevent pregnancy 67 67 67 80
> To abort a pregnancy 1 1 1 81
> To clean the womb/induce a period 17 17 17 98
> To treat vaginal discharge 2 2 2 100
Total 100 100 100
4.2.2 For how long have you been using quinine?
Duration of quinine usage
Frequency Percent Valid
Percent
Cumulative
Percent
Valid:
> Less than a year 61 61 61 61
> Between 1 and 2 years 18 18 18 79
> 2 - 3  years 8 8 8 87
> Over 3 years 13 13 13 100
Total 100 100 100
15
4.2.3 Where did you buy quinine ?
Source of quinine procurement
Frequency Percent Valid
Percent
Cumulative
Percent
Valid:
> Pharmacy 97 97 97 97
> Doctor 2 2 2 99
> Clinic/Hospital 1 1 1 1 0 0
Total 1 0 0 1 0 0 1 0 0
4.2.4 Were you ever counseled in the use o f quinine?
Professional counseling
Frequency Percent Valid
Percent
Cumulative
Percent
Valid:
> Yes 35 35 35 35
o£A 65 65 65 1 0 0
Total 1 0 0 1 0 0 1 0 0
4.2.5 Did you ask any health care professional about indications o f quinine?
Request for advice
Frequency Percent Valid
Percent
Cumulative
Percent
Valid:
> Yes 41 41 41 41
o£A 59 59 59 1 0 0
Total 1 0 0 1 0 0 1 0 0
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4.2.6 Who advised you to use quinine ?
Source of advice
Frequency Percent Valid
Percent
Cumulative
Percent
Valid:
> Family member 25 25 25 25
> Friend 47 47 47 72
> Pharmacist 7 7 7 79
> Nurse 9 9 9 88
> Doctor 12 12 12 100
Total 100 100 100
4.2.7 Have you ever used quinine for contraceptive purposes? 
Quinine as a contraceptive
Frequency Percent Valid
Percent
Cumulative
Percent
Valid:
> Yes 62 62 62 62
oZA 38 38 38 1 0 0
Total 1 0 0 1 0 0 1 0 0
4.2.8 Is quinine an effective contraceptive?
Perceived efficacy
Frequency Percent Valid
Percent
Cumulative
Percent
Valid:
> Yes 72 72 72 72
o£A 28 28 28 1 0 0
Total 1 0 0 1 0 0 1 0 0
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4.2.9 What dosage do you use ? 
Dosages
Frequency Percent Valid
Percent
Cumulative
Percent
Valid:
> 1 tablet/month at any time 34 34 34 34
> 1 tablet / week 7 7 7 41
> 2 tablets /week 1 1 1 42
> 2 tablets 3x daily for 7 days 5 5 5 47
> 1 tablet after sexual intercourse 4 4 4 51
> 2 tablets after sexual intercourse 6 6 6 57
> 1 or 2 tablets when necessary for nocturnal cramps 3 3 3 60
> 1 tablet /month on the day that period is due 15 15 15 75
> 4 tablets at once to induce abortion 1 1 1 76
> 2 tablets when necessary to prevent pregnancy 4 4 4 80
> 1 tablet/month on the same day of the month 3 3 3 83
> 2 tablets daily during a stay in a malaria area 1 1 1 84
> 3 tablets/month on 1st, 15th and 30th 1 1 1 85
> 1 tablet daily for 4 days 1 1 1 86
> 1 tablet/month between 14th and 16th day of 5 5 5 91
menstrual cycle
> 2 tablets/month on 15th and 28th days of menstrual 2 2 2 93
cycle
> 1 tablet daily for 5 days after period stops 1 1 1 94
> 2-3 tablets/month during last week of menstrual 3 3 3 97
cycle
> 2-4 tablets on any day of menstrual cycle 2 2 2 99
> 1 tablet daily from 14th -20th day of menstrual 1 1 1 100
cycle
Total 100 100 100
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4.2.10 What is your preferred method o f contraception?
Personal preference
Frequency Percent Valid
Percent
Cumulative
Percent
Valid:
> Quinine 57 57 57 57
> Condom 9 9 9 66
> Hormonal contraceptive pill 2 0 2 0 2 0 86
> Injection 11 11 11 97
> None 3 3 3 1 0 0
Total 1 0 0 1 0 0 1 0 0
4.2.11 What is your population group?
Ethnic group / Nationality Frequency Percent Valid
Percent
Cumulative
Percent
Zulu 38 38 38 38
Sotho 16 16 16 54
Tswana 4 4 4 58
Xhosa 13 13 13 71
Ndebele 2 2 2 73
Mswathi 1 1 1 74
DRC 4 4 4 78
Zimbabwe 16 16 16 94
Nigeria 2 2 2 96
Malawi 2 2 2 98
White/Co loured 2 2 2 100
Total 100 100 100
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4.3 Cross tabulations
4.3.1 Reason for quinine usage vs. gross monthly income
Gross monthly income
U
ne
m
pl
oy
ed
Le
ss
 th
an
 
R1
00
0
R1
00
0 
- 
R1
99
9
R2
00
0-
R2
99
9
Ov
er
R3
00
0
■5H
R
ea
so
n 
fo
r q
ui
ni
ne
 u
sa
ge
Treat/prevent
malaria
Count
Percent
2
20.0
4
40.0
1
10.0
1
10.0
2
20.0
10
100.0
Prevent/treat
nocturnal
cramps
Count
Percent
1
33.3
2
66.7
3
100.0
Prevent
pregnancy
Count
Percent
27
40.3
19
28.3
15
22.4
2
3.0
4
6.0
67
100.0
Abort a 
pregnancy
Count
Percent
1
100.0
1
100.0
Clean the 
womb/induce 
a period
Count
Percent
4
23.5
9
52.9
4
23.6
17
100.0
Treat vaginal 
discharge
Count
Percent
1
50.0
1
50.0
2
100.0
Tota
Perc<
count
mt
35
35.0
32
32.0
21
21.0
3
3.0
9
9.0
100
100.0
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4.3.2 Reason for quinine usage * coded age
Coded age (years)
Total
16
-2
0
20
-2
5
25
-3
0
30
-3
5
35
-4
0
O
ve
r 4
0
To treat /prevent Count 2 1 4 2 1 10
malaria Percent 10 10 40 20 10 100
To treat /prevent Count 1 2 3<DOX) nocturnal cramps Percent 33.3 66.7 100.0
To prevent Count 3 23 26 8 5 2 67
<D
.g pregnancy Percent 4.5 34.3 38.8 11.9 7.5 3.0 100.0
.3 To abort a Count 1 1
Er pregnancy Percent 100. 100.0
M 0
&o To clean the Count 1 7 2 2 3 2 17
CO womb/ induce a Percent 5.9 41.1 11.8 11.8 17.6 11.8 100.0
£ period
To treat a vaginal Count 2 2
discharge Percent 100.0 100.0
Total Count 4 33 32 14 10 7 100
Percent 4.0 33.0 32.0 14.0 10.0 7.0 100.0
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4.3.3 Reason for quinine use * ethnic group
Ethnic group
Zu
lu
So
th
o
Ts
w
an
a
X
ho
sa
N
de
be
le
D
RC
Zi
m
ba
bw
e
N
ig
er
ia
M
al
aw
i
M
sw
at
hi N
%
Re
as
on
 fo
r q
ui
ni
ne
T o treat/ 
prevent 
malaria
Count
Percent
2
20
1
10
4
40
l
10
2
20
10
100.0
T o treat/ 
prevent 
nocturnal 
cramps
Count
Percent
1
100
1
100.0
To
prevent
pregnancy
Count
Percent
27
40.3
11
16.4
3
4.5
10
14.9
2
3.0
13
19.4
1
1.5
67
100.0
To abort a 
pregnancy
Count
Percent
1
100
1
100.0
To clean  
the w om b/ 
induce a 
period
Count
Percent
6
35.3
3
17.6
1
5.9
3
17.6
2
11.8
2
11.8
17
100.0
To treat a 
vaginal 
discharge
Count
Percent
1
50
1
50
2
100.0
Count
Percent
(n)
(%)
38
38 .8
16
16.3
4
4.1
13
13.3
2
2
4
4.1
16
16.3
2
2
2
2
1
1
98
99.9
Note: White and coloured subjects are not included in the above table as they do not 
represent an ethnic group but a race group.
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4.3.4 Reason for quinine use * race
Race
Black Black Coloured White Total
(South (African
African) country)
To treat Count 3 7 10
/prevent
malaria
Percent 30 70 100.0
To treat Count 1 1 1 3
/prevent Percent 33.3 33.3 33.3 99.9
<D nocturnal
.S
fH
cramps
'3 To prevent Count 54 13 67
pregnancy Percent 80.6 19.4 100.0eg
£ To abort a Count 1 1ocnc3<9
pregnancy Percent 100 100.0
To clean the Count 13 4 17
womb/ 
induce a 
period
Percent 76.5 23.5 100.0
To treat a Count 2 2
vaginal
discharge
Percent 100 100.0
Total Count 74 24 1 1 100
Percent 74.0 24.0 1.0 1.0 100.0
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4.4 Data analysis
The statistical software that has been used in the data analysis is SPSS (Stastical Product 
and Service Solutions), and Microsoft Excel has been used in the graphing.
P-value tor Sig. Value).
p-value < 0.05 implies significant difference, otherwise no significant difference.
Table 4.4.1 Reason for quinine use
Frequency Percent Valid percent Cumulative
percent
Not to prevent 
pregnancy
33 33.0 33.0 33.0
To prevent 
pregnancy
67 67.0 67.0 100.0
Total 100 100.0 100.0
‘Not to prevent pregnancy’ includes:
> to treat/prevent malaria
> to treat/prevent nocturnal cramps
> to abort a pregnancy
> to ‘clean the womb’/induce a period
> to treat a vaginal discharge
Table 4.4.2 Duration of use
Frequency Percent Valid percent Cumulative percent
Less than a year 61 61.0 61.0 61.0
A year or more 39 39.0 39.0 100.00
Total 100 100.0 100.0
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Table 4.4.3 Who advised you to use quinine?
Frequency Percent Valid percent Cumulative
percent
Family
member
25 25.0 25.0 25.0
Friend 47 47.0 47.0 72.0
Professional 
person *
28 28.0 28.0 100.0
Total 100 100.0 100.0
* Professional person refers to doctor, nurse or pharmacist.
Table 4.4.4 Race
Frequency Percent Valid percent Cumulative
percent
Not a black 
South African
26 26.0 26.0 26.0
Black(South
African)
74 74.0 74.0 100.0
Total 100 100.0 100.0 100.0
All other racial groups are listed as ‘Mot a black South African’
Table 4.4.5 Ethnic groupings
Frequency Percent Valid percent Cumulative
percent
Nguni 54* 54.0 54.0 54.0
Sotho and Tswana 20 20.0 20.0 74.0
Others 26 26.0 26.0 100.0
Total 100 100.0 100.0
*Nguni includes Zulu, Xhosa, Ndebele and Mswathi
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Table 4.4.6 Cross tabulations (duration of use vs reason for quinine use)
How long have you 
been using quinine
Total
Less than a 
year
A year or 
more
Reason
For
quinine
Use
Not to prevent 
pregnancy
Count 22 11 33
Percent 66.7 33.3 100.0
To prevent 
pregnancy
Count 39 28 67
Percent 58.2 41.8 100.0
Total
Count 61 39 100
Percent 61.0 39.0 100.0
Chi-square tests
Value Df Asymp.Sig.(2 sided)
Pearson Chi-square 13.564* 2 0.001
Likelihood ratio 13.107 2 0.001
Linear-by-linear association 8.480 1 0.004
N of valid cases 100
* No cells (0.0%) have an expected count less than 5. The minimum expected count is 
8.25. There is a significant difference between the reasons for quinine use and the duration 
of use (p=0.001).
4.4.7 Cross-tabulation (race vs reason for quinine use)
Race
TotalNot a black 
(South African)
Black
(South
African)
R
ea
so
n 
fo
r 
qu
in
in
e 
us
e Not to prevent 
pregnancy
Count 13 20 33
Percent 39.4 60.6 100.0
To prevent 
pregnancy
Count 13 54 67
Percent 19.4 80.6 100.0
Total Percent 26.0 74.0 100.0
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Chi-Square test
Value Df Asymp. sig. 
(2 sided)
Exact sig. (2 
sided)
Exact sig. 
(1-sided)
Pearson Chi-square .665** 1 .415
Continuity
correction*
.357 1 .550
Likelihood ratio .672 1 .412
Fisher’s exact test .514 .277
Linear-by-linear
association
.658 1 .417
N of valid cases 100
* Computed only for a 2x2 table
** No cells (0.0%) have expected count less than 5. The minimum expected count is
12.87.
Remark: There is no association between the reason behind the use of quinine (in 
particular for pregnancy prevention) and the race group using it (p = 0.514), and is more 
than 0.05. The race groups using quinine has no significant effect on the reasoning behind 
the use of quinine.
4.4.8 Cross-tabulation (who advised quinine use vs reason for quinine use)
Who advised you
TotalFamily
Member
Friend Professional
person
R
ea
so
n 
fo
r 
qu
in
in
e 
us
e Not to prevent 
pregnancy
Count 6 10 17 33
Percent 18.2 30.3 51.5 100.0
To prevent 
pregnancy
Count 19 37 11 67
Percent 28.4 55.2 16.4 100.0
Total
Count 25 47 28 100
Percent 25.0 47.0 28.0 100.0
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Chi-square test
Value Df Asymp. sig. 
(2- sided)
Exact 
sig. (2- 
sided)
Exact sig. 
(1-sided)
Pearson Chi-square 4.593** 1 .032
Continuity correction* 3.612 1 .057
Likelihood ratio 4.430 1 .035
Fisher’s exact test .051 .030
Linear-by-linear
association
4.547 1 .033
N of valid cases 100
* Computed only for a 2x2 table
** No cells (0.0%) have expected count less than 5. The minimum expected count 
is 8.58.
Remark: The source of advice and the reasons for quinine use are not independent 
(p=0.032).
4.4.9 Cross-tabulation (ethnic group vs reason for quinine use)
Coded ethnic
TotalNguni Sotho & 
Tswana
Others
R
ea
so
n 
fo
r 
qu
in
in
e 
us
e
Not to 
prevent 
pregnancy
Count 14 6 11 31
Percent 45.2 19.3 35.5 100.0
To
prevent
pregnancy
Count 40 14 13 67
Percent 59.7 20.9 19.4 100.0
Total
Count 54 20 24 98
Percent 55.1 20.4 24.5 100.0
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Chi-Square Tests
Value Df Asymp.
Sig. (2-sided)
Pearson Chi-square 3.076* 2 0.215
Likelihood ratio 2.973 2 0.226
Linear-by-linear association 2.801 1 0.094
N of valid cases 98
* No cells (0.0%) have expected count less than 5. The minimum expected count is
6.33.
Remark: Ethnic groups and the reason for using quinine are independent (p=0.215).
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Chapter 5 Discussion
The subjects of the research were largely black South African and black immigrants from 
sub-Saharan countries. Language often presented a problem, in which case an interpreter 
was used. Some of the respondents, for example, stated that they used quinine to “clean the 
womb”. Upon further questioning, some used the term to mean to clean a vaginal 
discharge, whereas others used the term to describe the inducing of menstruation.
The most common reason for quinine usage was to prevent pregnancy (sixty-seven percent 
of all respondents). Quinine has not been approved for this indication. Only thirteen 
percent intended to use quinine for the indicated purposes of treating malaria (ten percent), 
or treating/preventing nocturnal cramps (three percent). (Table 4.2.1)
The majority of quinine users (sixty-one percent) had used quinine for less than a year, 
while thirteen percent had been using quinine for longer than three years. (Table 4.2.2)
The majority of the subjects purchased quinine from a pharmacy. The majority of doctors 
in the Hillbrow/Berea area are dispensing doctors, yet only two percent of the subjects 
purchased quinine from a doctor. (Table 4.2.3). The doctors in this area provide a cheap, 
subsidised family planning service and dispense mainly hormonal oral contraceptives. Oral 
contraceptives sell at between R2,00 and R5,00 per month’s supply at subsidised rates 
from contracted dispensing doctors. The retail price of one quinine tablet ranges from 
R3,00 to R4,50 in the different pharmacies in the area.
With regards to professional counselling, only thirty-five percent of the respondents were 
counselled by a healthcare professional (Table 4.2.4), whereas forty-one percent of quinine 
users had asked a healthcare professional about the indications and/or usage of quinine 
(Table 4.2.5). Pharmacists who were responsible for the sale of quinine to ninety seven 
percent of the respondents (Table 4.2.3) are in breach of their ethical responsibility where “ 
A pharmacist must not give an impression to a potential purchaser that any product
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associated with maintenance of health or a food supplement is efficacious when there is no 
evidence of efficacy”11
The majority of respondents did not ask the relevant healthcare professional for advice 
(fifty-nine percent)(Table 4.2.5). Pharmacists, however, as the main supplier of quinine, do 
not need to be solicited for advice, but advice should be offered and patients questioned 
about the intended usage of the product. As providers of schedule 1 and 2 medicines 
without the need for a prescription, pharmacists are ethically bound to provide advice on 
the safe and effective use of medicines supplied.12
Most of the respondents had been advised to use quinine by friends (forty-seven percent) 
or family members (twenty-five percent) (Table 4.2.6). In a study conducted in Nigeria, the 
majority o f people using emergency contraceptives (53,6%) received their information 
from friends. Of these, ninety percent of the respondents had received incorrect 
information13.
Twenty-eight percent of users were advised by healthcare professionals to use quinine 
(Table 4.2.6). Only thirteen percent of respondents used quinine for the manufacturer’s 
indications as listed in the package insert (Table 4.2.1); therefore, assuming that the 
thirteen percent were advised to use quinine for the correct indications, then fifteen percent 
of the respondents were advised to use quinine for contraceptive-related purposes by a 
healthcare professional.
Sixty-two percent of respondents had previously used quinine for contraceptive reasons 
(Table 4.2.7). On further questioning, many of the respondents stated that they had 
suffered unpleasant side effects from oral contraceptives and hormonal implant 
contraceptives. In addition, the convenient dosage of one tablet per month to be taken as 
recommended to the users, from mainly friends and family, is easier to comply with. In 
some populations in the United States (e.g. unmarried black adolescents), the failure rate of 
oral contraceptives is eighteen percent. Other factors contribute to oral contraceptive
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discontinuation. These include side effects, fears and misinformation about oral 
contraceptive side effects fuelled by negative media reports, and intermittent use.14
Seventy-two percent of respondents believed that quinine is an effective contraceptive 
(Table 4.2.8). The dosages varied considerably according to the indications for which it 
was used. Five percent had used quinine for the treatment/prevention of malaria at a 
dosage of two tablets three times daily for seven days. This is the correct dosage. Three 
percent had used quinine to treat nocturnal cramps at a dosage of one or two tablets when 
necessary. Thirty-four percent had used quinine as a contraceptive at a dosage of one tablet 
per month, but the interesting fact was that it was used at any time of the month. Fifteen 
percent had used quinine at a dose of one tablet per month on the day that their period was 
due. Ten percent of respondents had used quinine as a post-coital contraceptive, having 
taken one or two tablets after sexual intercourse. (Table 4.2.9).
Quinine was the most popular choice of contraceptive (fifty-seven percent) (Table 4.2.10), 
despite the fact that no evidence of its efficacy as a contraceptive exists. The 
misconception that it is effective as a once-monthly oral dose contraceptive is probably the 
reason for its popularity.
The majority of quinine users (thirty-five percent) were unemployed, while thirty-two 
percent of quinine users earned less than R1000.00 per month. Of these users, only six of 
the sixty-seven users had intended using quinine for indicated uses. Only nine percent of 
quinine users earned over R3000.00 per month and of these, two women had intended to 
use quinine to prevent or treat nocturnal cramps. It is possible that those earning over 
R3000.00 per month are of a more literate class, and also are on medical aid, so access to 
proper family planning services is not a problem (Table 4.3.1).
The most common age group of quinine users were 20-25 years old (thirty-three percent), 
whilst the next most common group was the 25-30 year old group (thirty-two percent). 
Sixty-nine percent of quinine users were below thirty years old. Of the study population,
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34.3% of the users between 20-25 years old, and 38.8% of the users between 25-30 years 
old, used quinine to prevent pregnancy. (Table 4.3.2).
The population group with the highest usage of quinine are the black South African 
(75.5%), whilst Zimbabweans were the next most common users (16.3%). Zulu women 
were the most common of all users at 38.8% of the total population survey. Zulu women 
accounted for 40.3% of users intending to use quinine as a contraceptive, and 35.3% of 
users who had intended to use quinine to ‘ clean the womb ’. Of the total respondents, two 
percent of Nigerian and 4.1% of users from DRC had intended to use quinine for the 
treatment/prevention of malaria, an indication for which quinine has been approved. (Table 
4.3.3).
Sixty-seven percent of users intended using quinine to prevent pregnancy, and seventeen 
percent to ‘clean the womb\ Black South African women were the largest group of quinine 
users (seventy-four percent of the total survey population). Only four South African 
women intended to use quinine for the indicated purposes of treating/preventing malaria or 
treating nocturnal cramps. Immigrants from other African countries accounted for twenty- 
four percent of total respondents, of whom seven users intended using quinine for the 
registered indications: (Table 4.3.4).
A Zimbabwean study on family planning knowledge showed that 0.8% of women used 
traditional/folk methods.15 It is, however, not stated what these methods are, but it is 
possible that quinine sulphate may be used for contraceptive purposes. Of the sixteen 
Zimbabwean respondents, thirteen had used quinine for contraceptive purposes, which 
suggests that the problem is a southern African one and not necessarily a South African 
one.
The time taken using quinine and the reasons for using quinine are not independent 
(p=0.001) (table 4.4.6). The highly significant result indicates that there is an association 
between the duration of quinine use and whether it was used for contraception or not. The 
pattern of responses in the two periods (less than a year and more than a year) is
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significantly different. The proportion of those who used it for contraception to the 
proportion who used it not for contraception differ significantly in the two time periods. 
Races of subjects and the reasons for using quinine are independent (p=0.514) (table 
4.4.7). The result indicates that there is no association between race and whether it was 
used for contraception or not. The pattern of responses in the two racial groups (Black 
South African and not a Black South African) is significantly not different. The proportion 
of subjects who used it for contraception does not differ significantly in the two racial 
groups.
The source of advice and the reasons for using quinine are not independent (p=0.032) 
(table 4.4.8). The highly significant result indicates that there is an association between the 
source of advice and whether it was used for contraception or not. The pattern of responses 
in the three sources of advice (family member, friend or professional person) is 
significantly different. The proportion of those who used it for the prevention of pregnancy 
differs significantly in the three advice sources.
Ethnic groups and the reason for using quinine are independent (p=0.215) (table 4.4.9).
The result indicates that there is no association between the ethnic groups and whether it 
was used for contraception or not. The pattern of responses in the three ethnic groups 
(Nguni, Sotho and Tswana, and other) is significantly not different. The proportion of 
those subjects who used quinine for contraception to the proportion who did not use it for 
contraception do not differ significantly in the three groups.
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Chapter 6 Conclusions and recommendations
6.1 Conclusions:
The results obtained in the study refer to a population studied in the Hillbrow-Berea area of
Johannesburg only.
> The most common reason for the purchase of quinine by black South African women 
was for the purpose of contraception.
> The majority of women who used quinine for contraception had used quinine for less 
than one year.
> Most users of quinine had purchased quinine from a pharmacy.
> The pharmacist did not counsel most of the users of quinine on the proper use of 
quinine.
> Less than half of the users had asked a healthcare professional about the proper use of 
quinine.
> Mostly friends were responsible for recommending quinine to be used as a 
contraceptive.
> The majority of black South African women believed that quinine is an effective 
contraceptive.
> The most common dosage of quinine for the purposes of contraception was one tablet 
(three hundred milligram strength) taken at any time of the month without reference to 
the menstrual cycle.
> Amongst all the purchasers of quinine by black South African women, the majority of 
women had used quinine as their preferred method of contraception.
> The majority of women who used quinine for contraception were unemployed.
'> The majority of women who used quinine as a contraceptive were Zulu.
> Women between the ages of twenty and thirty years old were the most common users 
of quinine as a contraceptive.
”r- The person who gave advice made a significant difference to the reason for quinine 
use.
> There was no significant difference between the reason for quinine use and the duration 
of use.
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6.2 Recommendations:
> Because of the wide dosing range used by the lay population, it is possible that 
overdosing may occur. The fatal oral dose of quinine for adults is about two to eight 
grams.9 Pharmacists need to question and appropriately counsel patients requesting 
quinine on the proper indications of use. Patients also need to be educated on the 
dangers of inappropriate use and very possible failure of quinine to act as a 
contraceptive.
> The manufacturers of quinine should state on the packaging that quinine is not a 
proven contraceptive or abortifacient.
> The Medicines Control Council should remove the schedule 1 status, as this is clearly 
being used as a loophole to dispense quinine as an over-the-counter preparation for the 
treatment of nocturnal cramps, whereas only three percent of the users who purchase 
quinine as an over-the counter preparation use it for this purpose (Table 4.2.1)
> Pharmacists should provide an alternate safe, cheap and efficacious family planning 
service. It seems that one of the reasons for using quinine is that it is relatively cheap at 
approximately R4,00 per tablet, especially for the users who believe and use one tablet 
per month as a menstrual regulator.
During counselling, some users had cited side effects of the hormonal contraceptive pill 
and injections as reasons for wanting to change to quinine. Many respondents had taken 
advice from friends and relatives to use quinine as a contraceptive, but many who were 
purchasing quinine for the first time were unsure of the dose to be taken or the time of the 
menstrual cycle at which it should be taken.
Those patients who had used quinine as a post-coital contraceptive^ were advised to use the 
Yupze regimen (E-GEN-C or Ovral) or the progestogen-only regimen (Norlevo), which 
appears to be better tolerated. Both of these regimens are available without prescriptions 
from pharmacies and are schedule 2 medicines. The recommended retail price of E-Gen-C 
is R64,36 and Norlevo retails at R68,90. Ovral, although recommended as a post coital 
contraceptive, is not registered for this indication with the Medicines Control Council. The 
Yupze regimen has long been recognised internationally as the preferred method for
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emergency contraception.16 Currently, post-coital methods of emergency use involve either 
administration of steroid hormones (oestrogens or oestrogen/progestin combinations), or 
less commonly, insertion of copper-releasing intra-uterine device (IUD). With the Yupze 
regimen, pregnancy can be prevented in up to 99.6% of cases and the risk of pregnancy is
17even lower with post-coital use of an IUD.
After counselling about the dangers of using quinine as a contraceptive, some patients had 
returned to purchase quinine, but when asked about its intended use, they stated that they 
had intended to use it to treat nocturnal cramps. The pharmacist in such a situation is 
placed in a dilemma, as quinine is schedule 1 for this indication, and as such, he is not in 
contravention of any legislation if quinine is dispensed to a patient requesting it for this 
indication.
In the United States of America (USA), quinine sulphate, which is widely prescribed for 
nocturnal leg cramps, used to be available over the counter. However, because 157 adverse 
drug reactions were reported from 1969-1992, the Food and Drug Administration (FDA) 
concluded that quinine was not safe for treatment of this disorder. In 1994 the FDA 
prohibited the marketing of quinine for nocturnal leg cramps and discontinued its 
availability in nonprescription form.18
Because of a lack of data on the use of quinine as a contraceptive or abortifacient, it is 
entirely possible for users to unintentionally overdose. The most common signs of 
overdose are cinchonism (tinnitus, deafness, nausea and vomitting). Cardiac arrhythmias 
and myocardial depression are signs of severe poisoning. Visual disturbances may occur, 
including total blindness.19
One of the most satisfying outcomes of the research project was the appreciation of a 
number of people for the advice given to them on both the misuse of quinine and the 
availability of proper contraception at family planning clinics and affiliated general 
practitioners. However, in general, users who had been using quinine as a contraceptive for
37
over a year dismissed the counselling as time wasted, as they had not fallen pregnant 
during their time of using quinine, and therefore regarded it as an effective contraceptive.
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Appendix 1
Questionnaire on quinine use in Hillbrow-Berea area
1. Is the quinine for your personal use?
Yes
No
2. Why are you using quinine?
To prevent or treat malaria
To diagnose myasthenia gravis (muscle weakness)
To prevent or treat nocturnal (night-time) cramps
To prevent pregnancy
To abort a pregnancy
Other reasons (please state)
3. For how long have you been using quinine for the reason as stated in question 2?
Less than 1 year
Between 1 and 2 years
2-3 years
More than 3 years
Previously, where did you buy quinine?
A Pharmacy
A Medical Practitioner (Doctor)
A Clinic or hospital
Other (please state)
Were you ever counselled on the use and/or indications of quinine sulphate?
Yes
No
Did you ask any healthcare professional (doctor, nurse, pharmacist) about the 
indications or dosage of quinine?
Yes
No
Who advised you to use quinine?
A Family member
A Friend
A Pharmacist
A Nurse
A Doctor
A Traditional Healer
Other (please state)
Have you ever used quinine sulphate for contraceptive purposes?
Yes
No
Do you think quinine is an effective contraceptive?
Yes
No
What dosage of quinine do you use?
1 Tablet per month
1 Tablet per week
2 Tablets per week
2 Tablets 3 times daily for 7 days
1 Tablet after sexual intercourse
2 Tablets after sexual intercourse
1 or 2 Tablets when necessary for nocturnal (night­
time) cramps
Other dosage (please state the dosage you use):
Are you currently taking any other contraceptive?
Yes
No
12. If yes, which of the following contraceptives are you using?
Condom
Hormonal contraceptive pill
Contraceptive injection
Spermicidal jelly
Other (please specify)
13. What is your preferred method of contraception?
Quinine
Condom
Hormonal contraceptive pill
Contraceptive injection
Spermicidal jelly
Other (please specify)
14. Your current gross monthly income is:
Less than R1000
R1000 -  R1999
R2000 -  R2999
Over R3000
15. Your population group is: (kindly note this question is for statistical purposes 
only)
Black (South Africa)
Black (Immigrant from African country)
Coloured
Indian
White
Other (please specify)
16. What is your age group?
16-20 years
20-25 years
25-30 years
30-35 years
35-40 years
Over 40 years
Thank you for taking the time to complete this questionnaire.
The information provided is to be used for research purposes and your identity is strictly 
confidential and will not be revealed.
Please ensure that the pharmacist has counselled you on the proper use of quinine before 
you leave.
Appendix 2
Confidentiality and anonymity
Hello, my name is Nishaan Jugram. I am a qualified pharmacist currently studying at the 
University Of the Witwatersrand. I would like to invite you to participate in research that 
I am doing, by completing the attached questionnaire.
The purpose of the questionnaire is to study the reasons that people use quinine. After 
filling in the questionnaire, I shall talk to you about quinine, and you may feel free to ask 
me any questions about the use or abuse of quinine, including any questions that you may 
have about it’s side effects and long term effects.
You are requested to answer the questions by marking the box that you feel best 
describes your answer. Please feel free to ask me any questions that you may have about 
the questionnaire, including any questions that you do not understand. I may be contacted 
at the telephone number below to answer any questions that you may have forgotten to 
ask when completing the questionnaire.
Your name is not required on the questionnaire and your answers as well as your identity 
shall remain confidential.
You are under absolutely no obligation to participate in the survey, and participation is 
totally voluntary.
Regards
Nishaan Jugram
Tel (011)642-1360 (work) 
082-783-4232 (cell)
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DECLARATION OF INVESTIGATORS
To be completed in duplicate and ONE COPY returned to the Secretary at Room 10001, 10th Floor, 
Senate House, University.
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research and l/we guarantee to ensure compliance with these conditions. Should any departure to be 
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Committee.
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